Thyrotropin-Releasing Hormone (TRH)
Also known as: TRH, thyroliberin, protirelin, thyrotropin-releasing factor
Hypothalamic releasing hormone — tripeptide neuropeptide (pyroGlu-His-Pro-NH2); acts via TRH receptor 1 (TRHR1) and TRH receptor 2 (TRHR2), G protein-coupled re
What it is
Thyrotropin-releasing hormone (TRH) is a short hypothalamic peptide used clinically in Japan for cerebellar movement disorders, studied in Western medicine for cancer-related fatigue, depression, and spinal cord injury, and employed globally as a diagnostic provocative test for pituitary and thyroid function. Biohackers and neurologists have explored its arousal-promoting and neuroprotective properties.
The scientific side
thyrotropin-releasing hormone (TRH) is a tripeptide (pyroGlu-His-Pro-NH2) synthesized predominantly in parvocellular neurons of the hypothalamic paraventricular nucleus (PVN), as well as in the dorsomedial hypothalamus, raphe nuclei, and multiple extrahypothalamic brain regions. TRH signals through two GPCRs — TRHR1 and TRHR2 — that couple to Gq/11 to activate phospholipase C, generating IP3 and DAG, which raises intracellular calcium and activates PKC, ultimately stimulating TSH and prolactin synthesis and release from anterior pituitary thyrotropes and lactotropes. At the level of the hypothalamic-pituitary-thyroid (HPT) axis, released TSH drives thyroid follicular cell synthesis of T3 and T4, which then exert long-loop negative feedback on both the pituitary and hypothalamus to suppress further TRH and TSH secretion. Critically, TRH also exerts numerous non-thyroidal central and peripheral actions that are largely independent of the HPT axis. In the central nervous system, TRH acts as an arousal peptide and analeptic — it reverses barbiturate- and ethanol-induced narcosis, promotes wakefulness, and counteracts behavioral depression in animal models. TRH neurons in the PVN and dorsomedial hypothalamus regulate brown adipose tissue (BAT) thermogenesis and energy expenditure through polysynaptic circuits to the sympathetic nervous system, independent of thyroid hormone changes, as demonstrated by chemogenetic activation studies. TRH modulates multiple neurotransmitter systems including acetylcholine (antiamnestic effects via cholinergic augmentation), dopamine, serotonin, and glutamate. In neurotrauma, TRH and its analogs show neuroprotective effects by antagonizing kappa-opioid receptors, reducing excitotoxicity, attenuating lipid peroxidation, and enhancing neuronal survival after spinal cord injury and traumatic brain injury. The peptide is rapidly degraded in plasma (half-life approximately 5 minutes) by pyroglutamyl peptidase II (PPII), a membrane-bound metallopeptidase highly expressed on thyrotrophes and at the median eminence, limiting its clinical utility as a drug candidate and driving development of metabolically stable analogs such as taltirelin and protirelin. TRH also stimulates prolactin release and participates in regulation of the immune system and inflammatory responses by modulating cytokine production, providing a mechanistic basis for its observed anti-inflammatory effects in cancer-related fatigue studies.
Class: Hypothalamic releasing hormone — tripeptide neuropeptide (pyroGlu-His-Pro-NH2); acts via TRH receptor 1 (TRHR1) and TRH receptor 2 (TRHR2), G protein-coupled receptors of the Gq/11 family
Administration & storage
- Administration
- Intravenous bolus (200–500 mcg over 15–30 seconds) — standard for TRH stimulation test and cancer-related fatigue research studiesIntravenous slow infusion — used in some Japanese spinocerebellar degeneration treatment protocols with protirelinIntrathecal injection — used in historical SMA trials and some depression case series; bypasses rapid plasma degradationOral (taltirelinanalog) — taltirelin (CeredistJapan) 5 mg twice daily; not applicable to native TRH due to rapid gastrointestinal degradationSubcutaneous — used in rodent research studies; not reported in human clinical use for native TRHIntranasal — investigated preclinically as a route to bypass blood-brain barrier; not established in human studies
- Storage
- Pharmaceutical protirelin solutions should be stored at 2–8°C (refrigerated) and protected from light; stable at room temperature for up to 24 hours. Lyophilized research-grade TRH powder should be stored at -20°C desiccated; reconstituted solutions are stable for approximately 48–72 hours at 4°C or can be aliquoted and frozen at -80°C for longer storage. TRH degrades rapidly in plasma (t1/2 approximately 5 minutes) due to pyroglutamyl peptidase II; ex vivo stability in plasma samples requires immediate processing or inhibitor addition. Taltirelin oral tablets should be stored per manufacturer instructions at room temperature.
- Cautions
- Transient cardiovascular effects: TRH IV bolus produces transient increases in blood pressure and heart rate in the majority of recipients; contraindicated or requires close monitoring in patients with ischemic heart disease, uncontrolled hypertension, or cardiac arrhythmias,Nausea and urge to urinate: common acute side effects within minutes of IV bolus; typically resolve within 15–30 minutes without intervention,Endocrine stimulation: TRH stimulates TSH and prolactin release; in patients with thyroid adenomas or hyperthyroidism, exaggerated TSH responses may precipitate thyrotoxic symptoms; in patients with prolactinomas, prolactin elevation may be pronounced,Seizure risk: TRH and some analogs have excitatory CNS properties; use with caution in patients with seizure disorders; TRH analogs have been reported to provoke seizures in susceptible animal models,Short plasma half-life and rapid degradation limit duration of action and predictability of systemic effects; intrathecal use carries procedural risks of infection, bleeding, and neurological injury,Research-grade peptide purity and sterility cannot be verified without third-party COA and endotoxin testing; self-administration of unverified TRH preparations carries risks of contamination, incorrect dosing, and acute cardiovascular events
Legal & regulatory status
Protirelin (synthetic TRH, brand name Relefact TRH) was previously FDA-approved as a diagnostic agent for the TRH stimulation test to assess pituitary TSH and prolactin secretory capacity, but was voluntarily withdrawn…
TRH is not listed on the WADA Prohibited List and has no known history as a performance-enhancing substance in competitive sport. As an endogenous hypothalamic peptide, exogenous TRH administration transiently elevates…
TRH (protirelin) is not approved as a therapeutic agent in Canada. Protirelin was historically available in Canada as a diagnostic provocative test agent for TSH and prolactin evaluation but is no longer in routine…
What it's studied for
- Spinocerebellar degeneration and cerebellar ataxia — approved therapeutic use (Japan) Human RCT / Long-term retrospective
- Cancer-related fatigue — investigational intravenous TRH Human RCT (small pilot)
- Acute spinal cord injury — neuroprotective pharmacotherapy (clinical trials) Human RCT (historical; inconclusive efficacy)
- Major depression and bipolar depression — antidepressant and anti-suicidal effects Human observational / small clinical studies
- Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS) — neuroprotection and cognitive enhancement Preclinical (Animal) / Early translational
- TRH stimulation test — diagnostic evaluation of hypothalamic-pituitary-thyroid axis Human observational (clinical diagnostic standard)
- Energy metabolism and brown adipose tissue thermogenesis — extrapituitary TRH neuron function Preclinical (Animal)
- Spinal muscular atrophy (SMA type II/III) — exploratory pharmacotherapy Human RCT (very low certainty; no significant efficacy demonstrated)
Safety signals
- Transient hypertension and tachycardia following IV bolus
- Nausea, flushing, urge to urinate, and metallic taste
- Prolactin elevation and hyperprolactinemia risk
- TSH-driven thyrotoxic effects with exaggerated TSH response
- CNS excitatory effects and potential seizure risk
- Rapid enzymatic degradation limiting predictability of intravascular dosing
- Endocrine axis disruption with repeated use — HPT axis suppression or dysregulation
No peer-reviewed studies indexed for this peptide yet.
Frequently asked
Is TRH available as an approved medication I can get from a doctor or pharmacy?
TRH (protirelin) is not currently available as an FDA-approved medication in the United States — the product was voluntarily withdrawn from the US market in the early 2000s. In Japan, the TRH analog taltirelin (Ceredist) is approved for spinocerebellar degeneration and is available by prescription. Some US compounding pharmacies may prepare TRH formulations, but these are not FDA-approved and lack the safety/quality assurance of licensed pharmaceuticals. You would need to discuss any therapeutic TRH use with a specialist physician who can evaluate whether it is appropriate for your situation.
What is the TRH stimulation test and why would my doctor order it?
The TRH stimulation test involves injecting a small amount of synthetic TRH intravenously to see how well your pituitary gland responds by releasing TSH and prolactin. Your doctor might order it to investigate possible resistance to thyroid hormone, to distinguish between different causes of unusual thyroid function test results, or in rare cases to evaluate a suspected pituitary tumor. Modern sensitive TSH blood tests have largely replaced the TRH stimulation test for routine thyroid diagnosis, so it is mainly used now in specialized academic endocrinology settings for complex diagnostic problems.
Can TRH help with depression or treatment-resistant depression?
Early research, including small clinical studies and case reports from the 1970s onward, showed that intravenous TRH produced rapid but short-lived antidepressant effects in some patients, possibly linked to its arousal-promoting and pro-monoaminergic properties. However, TRH's very short plasma half-life (about 5 minutes when given IV) means these effects are brief and it has not been developed into a standard antidepressant treatment. More recent metabolomics research found that esketamine — an approved treatment for treatment-resistant depression — raises TRH levels, suggesting TRH signaling may play a role in antidepressant responses. TRH is not an available or approved treatment for depression, and self-administering it carries significant risks.
I've read that TRH can improve energy and reduce fatigue — is this supported by evidence?
A small but rigorous randomized controlled pilot study in cancer survivors with significant fatigue did find that a single intravenous TRH injection significantly improved fatigue scores, sleep disturbance, and quality of life compared to placebo saline, with effects lasting up to 24 hours. The researchers also observed a reduction in the inflammatory marker CRP. While these findings are biologically plausible given TRH's known arousal and anti-inflammatory properties, the study had only 8 completers and has not been replicated in larger trials. No TRH preparation is currently approved for fatigue treatment, and the evidence base is too limited to recommend its use outside a carefully supervised clinical research context.
Is TRH on WADA's prohibited list for athletes?
TRH does not appear on the WADA Prohibited List and is not currently considered a banned performance-enhancing substance in competitive sport. While TRH transiently raises TSH and prolactin levels, its effects on athletic performance have not been studied and are not considered meaningful under current evidence. Athletes should always verify the current year's WADA Prohibited List before taking any peptide or hormone-related compound, as the list is updated annually.